AstraZeneca Imfinzi Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit If approved, this will be the first and only perioperative immunotherapy-based regimen in this setting AstraZeneca’s (AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review in the US for the treatment . . . This content is for …

Klotho Neurosciences to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators. On July 25, 2025,  Klotho Neurosciences, Inc. (KLTO) announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and also  longevity.  In addition to its core . . . This content is for paid subscribers. Please click here to subscribe …

GSK in the NEWS Today, GSK plc (GSK) announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). From GSK Court Horncastle, Senior Vice President at GSK, said,  “Too many people . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Eli Lilly Acquired Verve Therapeutics Eli Lilly and Company (LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (

AstraZeneca's Product Gefurulimab Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in disease severity at week 26.  Positive high-level results from a global, randomised, double-blind, placebo-controlled Phase III trial in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis showed that gefurulimab met its primary and all secondary endpoints. Data demonstrated a statistically significant and clinically meaningful improvement from baseline …

AstraZeneca in the NEWS Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company’s largest single Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% investment in a facility to date AstraZeneca (AZN) announces $50 billions of investment in the . . . This content is …

Axsome Therapeutics Axsome Therapeutics (AXSM) is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. The Company  delivers  scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Axsome industry-leading neuroscience portfolio includes FDA-approved . . . This content is for …

Friday, August 18, 2025 Solid Earning, revenue growth, President Trump signing crypto bills, and Crispr Therapeutics stocks finally surge with the stocks following are happening today in spite of  extreme bad weather in some states,  problems of important people from Epstein with many people visited him as friends not for anything else. While we enjoyed the surge of Crispr Therapeutics, we decided to remind the …

Q & A: Kiniksa Pharmaceuticals Q: Do you have any recent news from Kiniksa Pharmaceuticals?  A: Kiniksa Pharmaceuticals (KNSA) is a biopharmaceutical company that aims at  improving the lives of patients with debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need. The firm  focuses on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong . . . This …

The root-cause of the stock market’s volatility and inflation does not make sense as we are reading and hearing it. At the end of this week, we will post an article about this important subject, which will also explain the reason for the long pause of the Prohost Letter. Let’s have important news... Moderna to Report Q2 2025 Financial Results Moderna, Inc. (

Vertex Pharmaceuticals in the NEWS On Jul. 1, 2025, Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. From . . . This content is for paid subscribers. Please click here …

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer We wanted to know the reason for the acquisition so we looked at the BioNTech press release about the acquisition and found out the following news. On June 12, 2025, BioNTech (BNTX

Vertex Pharmaceuticals Simultaneous Announcements Vertex Pharmaceuticals (VRTX) announced simultaneous presentation and publication of updated data from Phase 1/2 portion of Phase 1/2/3 FORWARD-101 clinical trial in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in oral presentation at the American Diabetes Association (ADA . . . This content is for paid subscribers. Please click here to subscribe …

Cidara Therapeutics Cidara Therapeutics uses its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track …

Exelixis in the NEWS Exelixis (EXEL) announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Biotechnology and biopharmaceutical firms were doing great until the day the COVID-19 pandemic changed the lives of the world's population, killing millions worldwide. This distress impacted humanity's peace, stability and economy, bringing in unparalleled inflation, in addition to wars.    Analysts told investors to buy a stocks and then told them to sell those same stocks a few days later.  This practice made our picked …

Alnylam Pharmaceutical's News Today is Great Before we get to the press release from Alnylam Pharmaceuticals we remind that tomorrow, Tuesday, June 10, 2025,  Akero Therapeutics’ management will present at Goldman Sachs 46th Annual Global Healthcare Conference at 2:40 pm Et. The presentation will be available through the investor relations section of the company’s website at www.akerotx.com. An archived replay will be available for those …

Soleno Therapeutics Soleno Therapeutics (SLNO) announced that’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA). From Soleno Therapeutics “The validation . . . This content is for paid subscribers. Please click here to subscribe or …

Vera Therapeutics As expected, Vera Therapeutics (VERA) product Ataticept achieved proteinuria reduction in ORIGIN Phase 3 trials in adults with IgA nephropathy. This is indeed great news! The trial met the primary endpoint at week 36. Ataticept has achieved 46%reduction from baseline and 42%reduction compared to placebo on wek 36. Vera is not sharing cGFR at this time . . . This content is for …

Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Currently, many investors, including us, believe that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.